Furiex Pharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY13 | FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|---|
| Revenue | $39.3M | $2.6M | $4.5M | $9.0M | $6.3M |
| Operating income | $10.1M | −$9.5M | −$48.6M | −$49.5M | −$8.3M |
| Net income | $9.0M | −$9.8M | −$49.0M | −$54.7M | −$8.9M |
| Total assets | $88.4M | $94.8M | $95.1M | $132.6M | — |
| Total liabilities | $70.0M | $57.2M | $20.8M | $14.1M | — |
| Equity | $18.4M | $37.6M | $74.3M | $118.5M | $49.3M |
| EPS (diluted) | $0.82 | — | — | — | — |
| Shares out. | 10.0M | 9.9M | 9.9M | 9.9M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2013- Operating margin
- 25.6%
- Net margin
- 22.8%
- Return on equity
- 48.6%
- Return on assets
- 10.1%
- Return on capital (ROCE)
- 15.4%
- Liabilities / assets
- 79.1%
- Debt / equity
- 3.80×
- Book value / share
- $1.84
- Revenue growth (YoY)
- 1386.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2013- Altman Z″ (distress)
- -3.64distress
- Accruals / assets
- 36.3%high accruals
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJul 3, 2014
- Shareholder vote · Other material eventJul 1, 2014
- Shareholder voteMay 28, 2014
- Results of operations · Other material eventMay 7, 2014
- Entered a material agreement · Other material eventApr 29, 2014
- Results of operationsMar 11, 2014
- Other material eventFeb 4, 2014
- Results of operationsNov 6, 2013
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 17, 2015
- SC 13G/ACONSONANCE CAPITAL MANAGEMENT LPFeb 17, 2015
- SC 13G/ASCHEDULE 13GFeb 6, 2015
- 15-12BFORM 15Jul 14, 2014
- SC 13D/ASCHEDULE 13D AMENDMENT NO. 1Jul 9, 2014
- EFFECTJul 7, 2014
- 4FORM 4 SUBMISSIONJul 7, 2014
- SC 13DJul 7, 2014
- 4FORM 4Jul 7, 2014
- 4FORM 4Jul 7, 2014
- 4FORM 4Jul 7, 2014
- 4FORM 4Jul 7, 2014
- 4FORM 4Jul 7, 2014
- 4FORM 4Jul 7, 2014
- 4FORM 4Jul 7, 2014